Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Your medical team (MDT) has decided to refer you for a type of radiation treatment called PRRT
• You have been diagnosed with a neuroendocrine tumour (NET) originating from the gut, pancreas, or stomach (or a NET of unknown origin but thought to come from that area), confirmed by a tissue sample, that cannot be removed by surgery — regardless of tumour grade
• Your cancer has spread to other parts of the body and is getting worse, based on standard medical imaging measurements
• You have at least one tumour that can be measured on a CT or MRI scan with contrast dye
• A special scan (PET-DOTATOC) done within the last 4 months shows that your tumour cells have a specific receptor on their surface (meaning the treatment can target them)
• Most of your tumours — including all the ones chosen for measurement — show up on that special scan as targetable
• You are able to carry out most daily activities (a score of 60 or above on a standard health scale called Karnofsky — confirm with trial site)
• Your doctors expect you to live for more than 6 months
• You are 18 years of age or older

Who may not be able to join:

• You are pregnant or breastfeeding
• You have a known allergy to any of the ingredients used in the treatment, including lutetium-177, certain scan tracers, or related compounds (confirm with trial site)
• You have a known allergy to lysine, arginine, or other ingredients in a protective solution given alongside the treatment to protect your kidneys
• You cannot have an MRI scan for any reason
• You have had external radiation therapy to your NET tumours or a certain type of internal radiation therapy to the liver within the last 12 weeks, if that treatment was extensive
• You are currently receiving other anti-cancer treatments (not counting a type of medication called somatostatin analogues) that have not been stopped for at least 4 weeks
• Your tumour is a mixed type combining neuroendocrine and non-neuroendocrine cells (called MiNEN)
• Your tumour is classified as a neuroendocrine carcinoma (a specific aggressive type)
• You have brain metastases (cancer that has spread to the brain) that have not been controlled for at least 3 months
• You have severe heart failure (classified as NYHA grade 3 or 4 — confirm with trial site)
• You are unable to stop certain medications (long-acting or short-acting somatostatin analogues) for the required period before treatment
• Your bone marrow, liver, or kidney function is not at a safe enough level, based on blood tests done within the last month — this includes things like low platelet count, low haemoglobin (anaemia), poor kidney filtration rate, or certain liver markers being too high or too low (confirm specific values with trial site)
• You have previously had PRRT (the same type of treatment this trial is studying)
• You have another active and progressing cancer diagnosed within the last 3 years (except certain minor skin cancers or early-stage cervical cancer)
• You are not willing or able to sign a written consent form
• You are legally unable to make your own decisions or are in a restricted freedom situation (confirm with trial site)
• You are not enrolled in a French social security or equivalent health coverage scheme (this criterion suggests the trial is based in France — confirm with trial site)
• You are receiving State Medical Aid (a specific French healthcare assistance programme — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.